Dextropropoxyphene withdrawal from a French university hospital: Impact on analgesic drug consumption

Fundamental and Clinical Pharmacology

Volumn 23, Issue 2, 2009, Pages 247-252

  Gaubert, Sabine ^a   Vié, Martine ^b   Damase Michel, Christine ^b,c   Pathak, Atul ^b,c   Montastruc, Jean Louis ^b,c  

^a Paul Sabatier University   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Adverse drug reactions; Analgesic drugs; Dextropropoxyphene; Drug committee; Drug utilization study; Pharmacoepidemiology

Indexed keywords

ACETYLSALICYLIC ACID; CODEINE; DEXTROPROPOXYPHENE; FENTANYL; HYDROMORPHONE; MORPHINE; MORPHINE SULFATE; NALBUPHINE; NEFOPAM; OXYCODONE; PARACETAMOL; TRAMADOL;

ARTICLE; CONTROLLED STUDY; DRUG INFORMATION; DRUG USE; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; WORLD HEALTH ORGANIZATION;

ACETAMINOPHEN; AGED; ANALGESICS; ANALGESICS, OPIOID; DEXTROPROPOXYPHENE; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; FORMULARIES AS TOPIC; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; OVERDOSE; PAIN; PHARMACY SERVICE, HOSPITAL;

EID: 62849123800     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00661.x     Document Type: Article

References (19)

1. Gutstein H.B., Akil H. Opioid analgesics, in : Hardman J.G., Limbird L.E. (Eds Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 10th edn, McGraw-Hill, New York, 2001, pp. 547 590.
2. Li Wan Po A., Zhang W.Y. Systematic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol. Br. Med. J. (1997) 315 1565 1571.
3. Collins S.L., Edwards J.E., Moore R.A., McQuay H.J. Single dose dextropropoxyphene, alone and with paracetamol (acetaminophen) for postoperative pain. Cochrane Database Syst. Rev. (2000) 2 CD 001440.
4. Hawton K., Simkin S., Gunnell D., Bennewith O., Turnbull P., Kapur N. A multicentre study of coproxamol poisoning suicides on coroners' records in England. Br. J. Clin. Pharmacol. (2005) 59 207 212.
5. Prescrire Rédaction. Dextropropoxyphene combinations: Swedish market withdrawal. Prescrire Int. (2006) 15 20.
6. Medicines and Health Care Products Regulatory Agency. Withdrawal of co-proxamol. Available at: http://www.mhra.gov.uk/mhra/ CurrentProblemsInPharmacovigilance ; last accessed on 16 June 2008.
7. Dextropropoxyphene. Martindale: The Complete Drug Reference, 35th edn, Pharmaceutical Press, London, 2007.
8. World Health Organisation. WHO's Pain Relief Ladder. Available at: http://www.who.int/cancer/palliative/painladder/en/ ; last accessed on 2 June 2008.
9. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. Available at: http://www.who.no/atcddd/ ; last accessed 2 June 2008.
10. Summers K.H., Szeinbach S.L. Formularies: the role of pharmacy-and-therapeutics (P&T) committees. Clin. Ther. (1993) 15 433 441.
11. Compte-rendu du Comité Antalgiques du 13 Février. 2006, Comité du Médicament du CHU de Toulouse, 22 May 2006.
12. Comité de lutte contre la douleur du CHU de Toulouse. Procédure d'utilisation du patch de fentanyl Durogésic®, CLUD06. Available at: http://www.chu-toulouse.fr/IMG/pdf/DUROGESIC-version-pour- intranet.pdf.; last accessed on 2 June 2008
13. World Health Organisation. Cancer Pain Relief: With a Guide to Opioid Availability, 2nd edn, World Heath Organisation, Geneva, 1996.
14. Carvajal García-Pando A., Martín Arias L., Martín de Diego I., Velasco Martin A. Aspirin and paracetamol: changing pattern of use in Spain. Pharmacoepidemiol. Drug Saf. (1995) 4 381 382.
15. Agence Française de Sécurité Sanitaire des Produits de Santé. Les ventes de médicaments aux officines et aux hôpitaux en France - Chiffres-clés. 2005. Available at: http://afssaps.sante.fr/htm/5/rapport-vente-medicament-chiffre-2005.htm ; last accessed 12 March 2008.
16. Edouard B., Gaillard K. Evaluation du coulage médicamenteux en distribution globale. Gest. Hosp. (2002) 418 549 550.
17. Hoover R.C., McCormick W.C., Harrison W.L. Pilferage of controlled substances in hospitals. Am. J. Hosp. Pharm. (1981) 38 1007 1010.
18. Carlson G.M., Castile J.A., Janousek J.P. Guidelines for the prevention and detection of controlled substance diversion. Hosp. Pharm. (1988) 23 1057 1059.
19. Direction de l'Hospitalisation et de l'Organisation des Soins. Circulaire DHOS/E2/2002/266 du 30 Avril 2002. Available at: http://www.sante.gouv.fr/htm/ dossiers/prog-douleur/doc-pdf/circ020430.pdf.